Physician profile
Srinivasu Chamarthy
NPI 1912137647
$6,001.21
in general payments reported to CMS, 2019-2025
60 companies · $904 in 2025
The $904 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.45 · 2020: $91.27 · 2021: $1,141 · 2022: $1,576 · 2023: $1,172 · 2024: $1,030 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,769 · Education: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,768.62 |
| Education | $337.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $432.01 | 2021-2025 | Libtayo, Lynozyfic |
| Abbvie INC. | $418.05 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $386.57 | 2019-2023 | Imbruvica, Epkinly |
| E.R. Squibb & Sons, L.L.C. | $366.91 | 2021-2023 | Opdivo |
| Novartis Pharmaceuticals Corporation | $342.51 | 2021-2023 | |
| Pfizer INC. | $323.65 | 2021-2025 | |
| Astellas Pharma US INC | $249.42 | 2021-2024 | Padcev |
| Janssen Biotech, INC. | $218.85 | 2021-2023 | Darzalex, Erleada, Tecvayli |
| Merck Sharp & Dohme LLC | $181.11 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Rigel Pharmaceuticals, INC. | $169.55 | 2023-2024 | Rezlidhia, Tavalisse |
| Amgen INC. | $159.50 | 2019-2023 | Lumakras, Vectibix, Xgeva |
| Genzyme Corporation | $151.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $145.76 | 2021-2025 | Enhertu |
| Daiichi Sankyo INC. | $132.32 | 2021-2025 | Datroway, Enhertu |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivasu Chamarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.